Monoclonal antibody treatment for severe uncontrolled asthma in Spain: analytical map.

Monoclonal antibodies (mABs) have become available to treat more efficiently patients with severe uncontrolled asthma (SUA). However, the use of mABs is lower than expected given the prevalence of SUA, with significant disparities in the use of these treatments.

Bibliographic Details
Authors: Casas-Maldonado F, Álvarez-Gutiérrez FJ, Blanco-Aparicio M, Domingo-Ribas C, Cisneros-Serrano C, Soto-Campos G, Román-Bernal B, González-Barcala FJ
Format: article
Status:Published version
Publication Date:2022
Country:España
Institution:Institut d'Investigació i Innovació Parc Taulí (I3PT)
Repository:r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
OAI Identifier:oai:i3pt.fundanetsuite.com:p1692
Online Access:https://i3pt.portalinvestigacion.com/publicaciones/1692
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85115130931&doi=10.1080%2f02770903.2021.1978483&partnerID=40&md5=7cfae083e0cc9408f6e634fe85ea7b27
Access Level:Open access
Keyword:Benralizumab, Dupilumab: Omalizumab, Mepolizumab, Reslizumab, Severe asthma, monoclonal antibodies
Description
Summary:Monoclonal antibodies (mABs) have become available to treat more efficiently patients with severe uncontrolled asthma (SUA). However, the use of mABs is lower than expected given the prevalence of SUA, with significant disparities in the use of these treatments.

Similar Items